Celgene is paying up under a February 2014 deal with Abide Therapeutics to exercise its option for ex-U.S. rights to its only clinical candidate.

Amgen has handed over $56.5 million and committed to up to $617 million more to buy into Arrowhead’s efforts to aim RNAi therapies at cardiovascular targets.

In our EuroBiotech roundup this week, Noxxon lists in Paris, Summit's DMD drug boards the fast track, Bavarian Nordic poaches a CMO from the NCI and more.

The FDA has put a full clinical hold on a Phase III trial of Alcobra's MDX, putting another barrier between the firm and its long-sought approval of the…

Acceleron has brought in a top commercial exec from Bayer, Habib Dable, to lead the company as it aims to plan for a marketed product.

Johnson & Johnson’s Janssen has licensed two early oncology assets to Tracon Pharmaceuticals through Phase I/II development, then the pharma has the…

Boehringer Ingelheim is making a bid in oncolytic viruses in a deal with preclinical ViraTherapeutics that’s worth up to €210 million. As part of the deal, the…

New research from the Human Microbiology Institute has shown that many diseases, from Alzheimer’s to cancer and others, could be linked to bacterial viruses, a…

MD Anderson scientists have pinpointed how melanoma tumors resist the cancer drug ipilimumab: genetic mutations in an immune pathway.